‘Paradigm-shifting’ treatment for pediatric diabetes cleared by FDA (opens in new tab)

Yale’s Kevan Herold was the senior investigator on a clinical trial which showed that the drug teplizumab — recently approved for pediatric patients with Stage 3 Type 1 diabetes — delays the progression of the disease.